Misplaced Pages

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 08:06, 3 November 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'StdInChI', 'StdInChIKey', 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

{{Drugbox | IUPAC_name = 3-{6-{amino}-3-methylpyridin-2-yl}benzoic acid | image = VX-807 skeletal.svg | alt = | caption =

| tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number = | ATCvet = | ATC_prefix = None | ATC_suffix = | PubChem = 16678941 | DrugBank =

| C=24|H=18|F=2|N=2|O=5 | molecular_weight = 452.407 g/mol | smiles = CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O | StdInChI = | StdInChIKey = }}

VX-807 is an experimental drug for the treatment of cystic fibrosis. The drug is designed to be effective in patients that have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. F508del, meaning that the amino acid phenylalanin in position 508 is missing, is found in about 90% of cystic fibrosis patients.

References

1. Pharmazeutische Zeitung (in German). 156 (37): 24–27. {{cite journal}}: Missing or empty |title= (help); Unknown parameter |authors= ignored (help)

This article has not been added to any content categories. Please help out by adding categories to it so that it can be listed with similar articles, in addition to a stub category. (November 2011)

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Uncategorized from November 2011
• Pharmacology stubs